These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 8895185)

  • 21. Eosinophilia-myalgia syndrome in patients ingesting a single source of L-tryptophan.
    Henning KJ; Jean-Baptiste E; Singh T; Hill RH; Friedman SM
    J Rheumatol; 1993 Feb; 20(2):273-8. PubMed ID: 8474064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The natural history of eosinophilia-myalgia syndrome in a tryptophan-exposed cohort in South Carolina.
    Sullivan EA; Kamb ML; Jones JL; Meyer P; Philen RM; Falk H; Sinks T
    Arch Intern Med; 1996 May; 156(9):973-9. PubMed ID: 8624177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tryptophan toxicity: a pharmacoepidemiologic review of eosinophilia-myalgia syndrome.
    Milburn DS; Myers CW
    DICP; 1991 Nov; 25(11):1259-62. PubMed ID: 1763543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1,1'-Ethylidenebis[tryptophan] induces pathologic alterations in muscle similar to those observed in the eosinophilia-myalgia syndrome.
    Emslie-Smith AM; Mayeno AN; Nakano S; Gleich GJ; Engel AG
    Neurology; 1994 Dec; 44(12):2390-2. PubMed ID: 7991132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan.
    Keating JP; Wardill K; Viggiano J
    N Z Med J; 1992 Aug; 105(939):317. PubMed ID: 1386918
    [No Abstract]   [Full Text] [Related]  

  • 26. Reduced severity of eosinophilia-myalgia syndrome associated with the consumption of vitamin-containing supplements before illness.
    Hatch DL; Goldman LR
    Arch Intern Med; 1993 Oct; 153(20):2368-73. PubMed ID: 8215741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eosinophilia-myalgia syndrome in Wisconsin.
    Butler JC; Davis JP
    Wis Med J; 1990 Dec; 89(12):687-91. PubMed ID: 2293489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Eosinophilia-myalgia syndrome after L-tryptophan intake].
    Zillikens D; Bammel A; Lurz C; Elsner P; Burg G
    Hautarzt; 1991 Mar; 42(3):154-7. PubMed ID: 2055764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eosinophilia-myalgia syndrome: myopathic electrodiagnostic characteristics.
    Tanhehco JL; Wiechers DO; Golbus J; Neely SE
    Muscle Nerve; 1992 May; 15(5):561-7. PubMed ID: 1584247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Environmental pathology. Mast cell and eosinophil infiltration in intestinal mucosa of Lewis rats treated with L-tryptophan implicated in human eosinophilia myalgia syndrome.
    DeSchryver-Kecskemeti K; Gramlich TL; Crofford LJ; Rader JI; Page SW; Needham LL; Hill RH; Sternberg EM
    Mod Pathol; 1991 May; 4(3):354-7. PubMed ID: 2068062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies with 1,1'-ethylidenebis(tryptophan), a contaminant associated with L-tryptophan implicated in the eosinophilia-myalgia syndrome.
    Sidransky H; Verney E; Cosgrove JW; Latham PS; Mayeno AN
    Toxicol Appl Pharmacol; 1994 May; 126(1):108-13. PubMed ID: 8184420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan.
    Allen JA; Peterson A; Sufit R; Hinchcliff ME; Mahoney JM; Wood TA; Miller FW; Whitfield ML; Varga J
    Arthritis Rheum; 2011 Nov; 63(11):3633-9. PubMed ID: 21702023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eosinophilia-myalgia syndrome not associated with the ingestion of nutritional supplements.
    Clauw DJ; Flockhart DA; Mullins W; Katz P; Medsger TA
    J Rheumatol; 1994 Dec; 21(12):2385-7. PubMed ID: 7699648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome.
    Williamson BL; Tomlinson AJ; Mishra PK; Gleich GJ; Naylor S
    Chem Res Toxicol; 1998 Mar; 11(3):234-40. PubMed ID: 9544622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A heretofore undisclosed crux of eosinophilia-myalgia syndrome: compromised histamine degradation.
    Smith MJ; Garrett RH
    Inflamm Res; 2005 Nov; 54(11):435-50. PubMed ID: 16307217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The eosinophilia-myalgia syndrome: what we know, what we think we know, and what we need to know.
    Clauw DJ; Pincus T
    J Rheumatol Suppl; 1996 Oct; 46():2-6. PubMed ID: 8895175
    [No Abstract]   [Full Text] [Related]  

  • 37. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome.
    Johnson KL; Klarskov K; Benson LM; Williamson BL; Gleich GJ; Naylor S
    J Rheumatol; 1999 Dec; 26(12):2714-7. PubMed ID: 10606395
    [No Abstract]   [Full Text] [Related]  

  • 38. Tryptophan-induced lung disease: an immunophenotypic, immunofluorescent, and electron microscopic study.
    Tazelaar HD; Myers JL; Strickler JG; Colby TV; Duffy J
    Mod Pathol; 1993 Jan; 6(1):56-60. PubMed ID: 8426858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan.
    Michelson D; Page SW; Casey R; Trucksess MW; Love LA; Milstien S; Wilson C; Massaquoi SG; Crofford LJ; Hallett M
    J Rheumatol; 1994 Dec; 21(12):2261-5. PubMed ID: 7699627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L-tryptophan syndrome: histologic features of scleroderma-like skin changes.
    Guerin SB; Schmidt JJ; Kulik JE; Golitz LE
    J Cutan Pathol; 1992 Jun; 19(3):207-11. PubMed ID: 1401345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.